Literature DB >> 23244119

Menopausal status modifies breast cancer risk associated with ESR1 PvuII and XbaI polymorphisms in Asian women: a HuGE review and meta-analysis.

Li-Wen Li1, Lei Xu.   

Abstract

BACKGROUND: Published data on the association between single nucleotide polymorphisms (SNPs) in the ESR1 gene and breast cancer susceptibility are inconclusive or controversial. The aim of this Human Genome Epidemiology (HuGE) review and meta-analysis was to derive a more precise estimation of this relationship.
METHODS: A literature search of Pubmed, Embase, Web of science and CBM databases was conducted from inception through September 1 th, 2012. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of association.
RESULTS: A total of five studies including 1,678 breast cancer cases and 1,678 general population controls in Asian populations were involved in this meta-analysis. When all the eligible studies were pooled into the meta-analysis, the higher transcriptional activity variant allele T of ESR1 PvuII (C>T) (rs2234693) in pre-menopausal breast cancer women showed a significant relation to increased risk (OR = 1.13, 95%CI: 1.01-1.28, P = 0.040) in contrast to their post-menopausal counterparts which showed non-significant increased risk (OR = 1.01, 95%CI: 0.87-1.18, P = 0.858). Nevertheless, no significant association between ESR1 XbaI (A>G) (rs9340799) polymorphism and the risk of breast cancer was observed in pre-menopausal and post-menopausal individuals.
CONCLUSION: Based on a homogeneous Asian population, results from the current meta-analysis indicates that the ESR1 PvuII (C>T) polymorphism places pre-menopausal breast cancer women at risk for breast cancer, while ESR1 XbaI (A>G) polymorphism is not likely to predict the risk of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23244119     DOI: 10.7314/apjcp.2012.13.10.5105

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  9 in total

1.  Comment on "Estrogen receptor alpha (ERS1) SNPs c454-397T>C (PvuII) and c454-351A>G (XbaI) are risk biomarkers for breast cancer development".

Authors:  Bei Wang; Fenlai Yuan
Journal:  Mol Biol Rep       Date:  2018-10-26       Impact factor: 2.316

2.  Alcohol consumption and breast cancer risk by estrogen receptor status: in a pooled analysis of 20 studies.

Authors:  Seungyoun Jung; Molin Wang; Kristin Anderson; Laura Baglietto; Leif Bergkvist; Leslie Bernstein; Piet A van den Brandt; Louise Brinton; Julie E Buring; A Heather Eliassen; Roni Falk; Susan M Gapstur; Graham G Giles; Gary Goodman; Judith Hoffman-Bolton; Pamela L Horn-Ross; Manami Inoue; Laurence N Kolonel; Vittorio Krogh; Marie Lof; Paige Maas; Anthony B Miller; Marian L Neuhouser; Yikyung Park; Kim Robien; Thomas E Rohan; Stephanie Scarmo; Leo J Schouten; Sabina Sieri; Victoria L Stevens; Schoichiro Tsugane; Kala Visvanathan; Lynne R Wilkens; Alicja Wolk; Elisabete Weiderpass; Walter C Willett; Anne Zeleniuch-Jacquotte; Shumin M Zhang; Xuehong Zhang; Regina G Ziegler; Stephanie A Smith-Warner
Journal:  Int J Epidemiol       Date:  2015-08-28       Impact factor: 7.196

3.  ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.

Authors:  Brian Leyland-Jones; Kathryn P Gray; Mark Abramovitz; Mark Bouzyk; Brandon Young; Bradley Long; Roswitha Kammler; Patrizia Dell'Orto; Maria Olivia Biasi; Beat Thürlimann; Vernon Harvey; Patrick Neven; Laurent Arnould; Rudolf Maibach; Karen N Price; Alan S Coates; Aron Goldhirsch; Richard D Gelber; Olivia Pagani; Giuseppe Viale; James M Rae; Meredith M Regan
Journal:  Breast Cancer Res Treat       Date:  2015-11-21       Impact factor: 4.872

4.  Association Between ESR1 PvuII, XbaI, and P325P Polymorphisms and Breast Cancer Susceptibility: A Meta-Analysis.

Authors:  Yiming Zhang; Ming Zhang; Xiaosong Yuan; Zhichen Zhang; Ping Zhang; Haojie Chao; Lixia Jiang; Jian Jiang
Journal:  Med Sci Monit       Date:  2015-10-04

5.  A Meta-Analysis of the Association between ESR1 Genetic Variants and the Risk of Breast Cancer.

Authors:  Taishun Li; Jun Zhao; Jiaying Yang; Xu Ma; Qiaoyun Dai; Hao Huang; Lina Wang; Pei Liu
Journal:  PLoS One       Date:  2016-04-12       Impact factor: 3.240

6.  Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial.

Authors:  Harriet Johansson; Kathryn P Gray; Olivia Pagani; Meredith M Regan; Giuseppe Viale; Valentina Aristarco; Debora Macis; Antonella Puccio; Susanne Roux; Rudolf Maibach; Marco Colleoni; Manuela Rabaglio; Karen N Price; Alan S Coates; Richard D Gelber; Aron Goldhirsch; Roswitha Kammler; Bernardo Bonanni; Barbara A Walley
Journal:  Breast Cancer Res       Date:  2016-11-08       Impact factor: 6.466

7.  Association of three single nucleotide polymorphisms of ESR1with breast cancer susceptibility: a meta-analysis.

Authors:  Xu Hu; Linfei Jiang; Chenhui Tang; Yuehong Ju; Li Jiu; Yongyue Wei; Li Guo; Yang Zhao
Journal:  J Biomed Res       Date:  2017-01-19

Review 8.  Association between ERα gene Pvu II polymorphism and breast cancer susceptibility: A meta-analysis.

Authors:  Zhen-Lian Zhang; Cui-Zhen Zhang; Yan Li; Zhen-Hui Zhao; Shun-E Yang
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

9.  Estrogen Receptor 1 Gene (ESR1) rs2234693 Polymorphism and Breast Cancer Risk in Saudi Women.

Authors:  Razan Jamaan Al-Amri; Mohammad Kdaimes H Alotibi; Rawya Ibrahim Al-Raddadi; Weam Talal Yehya Shebli; Emad Ibrahim Yagoub Fallatah; Ahmed Safar Alhujaily; Hiba Salaheldin Mohamed
Journal:  Asian Pac J Cancer Prev       Date:  2020-11-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.